Gufic Biosciences Limited (GUFICBIO.BO)
INR 317.25
(2.11%)
INR 317.25
(2.11%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 1.48 Billion INR | 6.3% |
| 2022 | 1.37 Billion INR | -9.2% |
| 2021 | 1.48 Billion INR | 76.25% |
| 2020 | 876.52 Million INR | 51.37% |
| 2019 | 579.04 Million INR | 13.36% |
| 2018 | 489.98 Million INR | 20.61% |
| 2017 | 435.03 Million INR | 70.75% |
| 2016 | 239.28 Million INR | 20.04% |
| 2015 | 203.46 Million INR | 36.58% |
| 2014 | 148.38 Million INR | 17.17% |
| 2013 | 126.56 Million INR | 17.65% |
| 2012 | 111.33 Million INR | 55.4% |
| 2011 | 70.7 Million INR | 16.69% |
| 2010 | 59.2 Million INR | 6.29% |
| 2009 | 52.51 Million INR | -6.09% |
| 2008 | 59.31 Million INR | 13.55% |
| 2007 | 52.11 Million INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 357.79 Million INR | 0.42% |
| 2023 Q3 | 368.78 Million INR | -7.12% |
| 2023 Q4 | 364.54 Million INR | -1.15% |
| 2023 FY | - INR | 6.3% |
| 2023 Q2 | 397.03 Million INR | 9.2% |
| 2023 Q1 | 363.58 Million INR | 0.74% |
| 2022 FY | - INR | -9.2% |
| 2022 Q3 | 341.48 Million INR | 2.15% |
| 2022 Q4 | 360.92 Million INR | 5.69% |
| 2022 Q1 | 335.53 Million INR | 11.36% |
| 2022 Q2 | 334.3 Million INR | -0.37% |
| 2021 Q3 | 342.48 Million INR | -5.22% |
| 2021 Q4 | 301.32 Million INR | -12.02% |
| 2021 Q1 | 468.76 Million INR | 44.48% |
| 2021 FY | - INR | 76.25% |
| 2021 Q2 | 361.34 Million INR | -22.92% |
| 2020 FY | - INR | 51.37% |
| 2020 Q4 | 324.44 Million INR | 18.18% |
| 2020 Q3 | 274.54 Million INR | -13.3% |
| 2020 Q2 | 316.65 Million INR | 666.76% |
| 2020 Q1 | 41.29 Million INR | -61.54% |
| 2019 Q4 | 107.38 Million INR | -28.34% |
| 2019 Q3 | 149.85 Million INR | 26.98% |
| 2019 Q2 | 118.01 Million INR | -10.34% |
| 2019 Q1 | 131.62 Million INR | -15.55% |
| 2019 FY | - INR | 13.36% |
| 2018 Q3 | 121.89 Million INR | -6.19% |
| 2018 FY | - INR | 20.61% |
| 2018 Q4 | 155.86 Million INR | 27.87% |
| 2018 Q2 | 129.93 Million INR | -17.81% |
| 2018 Q1 | 158.08 Million INR | 51.46% |
| 2017 Q1 | 74.93 Million INR | 92.94% |
| 2017 FY | - INR | 70.75% |
| 2017 Q3 | 130.79 Million INR | 24.13% |
| 2017 Q4 | 104.37 Million INR | -20.2% |
| 2017 Q2 | 105.36 Million INR | 40.62% |
| 2016 FY | - INR | 20.04% |
| 2016 Q2 | 66.01 Million INR | 2.15% |
| 2016 Q1 | 64.62 Million INR | 5.92% |
| 2016 Q4 | 38.83 Million INR | -43.1% |
| 2016 Q3 | 68.25 Million INR | 3.39% |
| 2015 Q1 | 36.8 Million INR | 22.17% |
| 2015 Q2 | 47.8 Million INR | 29.87% |
| 2015 Q3 | 56.52 Million INR | 18.24% |
| 2015 FY | - INR | 36.58% |
| 2015 Q4 | 61.01 Million INR | 7.94% |
| 2014 Q3 | 34.26 Million INR | -17.01% |
| 2014 Q4 | 30.13 Million INR | -12.07% |
| 2014 Q2 | 41.29 Million INR | -2.43% |
| 2014 Q1 | 42.31 Million INR | 16.66% |
| 2014 FY | - INR | 17.17% |
| 2013 Q2 | 29.56 Million INR | 2.77% |
| 2013 Q4 | 36.27 Million INR | 14.39% |
| 2013 FY | - INR | 17.65% |
| 2013 Q3 | 31.71 Million INR | 7.27% |
| 2013 Q1 | 28.76 Million INR | 1.66% |
| 2012 FY | - INR | 55.4% |
| 2012 Q1 | 24.84 Million INR | 56.57% |
| 2012 Q4 | 28.29 Million INR | 2.62% |
| 2012 Q3 | 27.57 Million INR | 3.48% |
| 2012 Q2 | 26.64 Million INR | 7.25% |
| 2011 Q3 | 16.52 Million INR | 0.0% |
| 2011 FY | - INR | 16.69% |
| 2011 Q4 | 15.86 Million INR | -3.98% |
| 2010 FY | - INR | 6.29% |
| 2009 FY | - INR | -6.09% |
| 2008 FY | - INR | 13.55% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 84.605% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 97.604% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 78.428% |
| Granules India Limited | 8.6 Billion INR | 82.793% |
| Indoco Remedies Limited | 2.64 Billion INR | 44.07% |
| Achyut Healthcare Limited | 524 Thousand INR | -282435.496% |
| Ajanta Pharma Limited | 12.56 Billion INR | 88.218% |
| Alkem Laboratories Limited | 24.19 Billion INR | 93.881% |
| Alpa Laboratories Limited | 86.12 Million INR | -1618.957% |
| Brooks Laboratories Limited | 41.72 Million INR | -3447.944% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | 37.182% |
| Bajaj HealthCare Limited | 444.51 Million INR | -233.056% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -0.098% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 98.323% |
| Eris Lifesciences Limited | 6.98 Billion INR | 78.809% |
| FDC Limited | 4.4 Billion INR | 66.365% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 86.949% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 78.424% |
| Ipca Laboratories Limited | 13.29 Billion INR | 88.868% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -357.703% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 1889.604% |
| Lasa Supergenerics Limited | -65.08 Million INR | 2374.871% |
| Laurus Labs Limited | 8 Billion INR | 81.508% |
| Lupin Limited | 36.96 Billion INR | 95.995% |
| Mankind Pharma Limited | 28.09 Billion INR | 94.73% |
| Medicamen Biotech Limited | 245.66 Million INR | -502.657% |
| Medico Remedies Limited | 150.37 Million INR | -884.51% |
| Megasoft Limited | 284.73 Million INR | -419.96% |
| NATCO Pharma Limited | 18.79 Billion INR | 92.123% |
| Piramal Pharma Limited | 13.05 Billion INR | 88.66% |
| RPG Life Sciences Limited | 1.28 Billion INR | -15.528% |
| Sigachi Industries Limited | 883.39 Million INR | -67.59% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 98.93% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 68.347% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -244.078% |
| Unichem Laboratories Limited | 742.35 Million INR | -99.431% |
| Wanbury Limited | 985.49 Million INR | -50.228% |
| Windlas Biotech Limited | 781.72 Million INR | -89.388% |
| ZIM Laboratories Limited | 462.09 Million INR | -220.384% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 97.367% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 139.678% |
| Divi's Laboratories Limited | 25.43 Billion INR | 94.178% |
| Hester Biosciences Limited | 539.47 Million INR | -174.433% |
| Procter & Gamble Health Limited | 3.01 Billion INR | 50.886% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -116.909% |
| Bal Pharma Limited | 345.59 Million INR | -328.391% |
| Strides Pharma Science Limited | 3.76 Billion INR | 60.674% |
| Venus Remedies Limited | 711.8 Million INR | -107.992% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 62.13% |
| Nectar Lifesciences Limited | 1.56 Billion INR | 5.327% |
| Shilpa Medicare Limited | 2.58 Billion INR | 42.794% |
| Aarti Drugs Limited | 3.24 Billion INR | 54.427% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | 43.202% |
| Suven Life Sciences Limited | -992.78 Million INR | 249.125% |
| Ind-Swift Limited | 1.06 Billion INR | -39.004% |
| Valiant Laboratories Limited | 12.73 Million INR | -11521.681% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 84.14% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 152.464% |
| Themis Medicare Limited | 562.6 Million INR | -163.147% |
| Hikal Limited | 2.69 Billion INR | 45.009% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 95.771% |
| Sequent Scientific Limited | 549.8 Million INR | -169.277% |
| Novartis India Limited | 1.26 Billion INR | -16.638% |
| Wockhardt Limited | 1.08 Billion INR | -37.082% |
| Jubilant Pharmova Limited | 8 Billion INR | 81.508% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -11234.298% |
| Neuland Laboratories Limited | 4.74 Billion INR | 68.82% |
| Morepen Laboratories Limited | 1.72 Billion INR | 14.222% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -415.086% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -746.253% |